BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 37938348)

  • 1. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
    Leonetti A; Verzè M; Minari R; Perrone F; Gnetti L; Bordi P; Pluchino M; Nizzoli R; Azzoni C; Bottarelli L; Lagrasta CAM; Mazzaschi G; Buti S; Gasparro D; Cosenza A; Ferri L; Majori M; De Filippo M; Ampollini L; La Monica S; Alfieri R; Silini EM; Tiseo M
    Br J Cancer; 2024 Jan; 130(1):135-142. PubMed ID: 37938348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
    Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
    J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Lee EJ; Oh SY; Lee YW; Kim JY; Kim MJ; Kim TH; Lee JB; Hong MH; Lim SM; Baum A; Woelflingseder L; Engelhardt H; Petronczki M; Solca F; Yun MR; Cho BC
    Clin Cancer Res; 2024 Apr; 30(8):1582-1594. PubMed ID: 38330145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
    Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
    Roper N; El Meskini R; Maity T; Atkinson D; Day A; Pate N; Cultraro CM; Pack S; Zgonc V; Weaver Ohler Z; Guha U
    Cancer Res Commun; 2024 Feb; 4(2):337-348. PubMed ID: 38276867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
    Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
    Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.
    Al-Obeidi E; Kelly K; Gandara DR; Riess JW
    JCO Precis Oncol; 2024 Apr; 8():e2300677. PubMed ID: 38603654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.
    Inutsuka Y; Iwama E; Shiraishi Y; Yoneshima Y; Shibahara D; Tanaka K; Okamoto I
    Respir Investig; 2024 May; 62(3):334-338. PubMed ID: 38412569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
    La Monica S; Vacondio F; Eltayeb K; Lodola A; Volta F; Viglioli M; Ferlenghi F; Galvani F; Galetti M; Bonelli M; Fumarola C; Cavazzoni A; Flammini L; Verzè M; Minari R; Petronini PG; Tiseo M; Mor M; Alfieri R
    Sci Rep; 2024 Mar; 14(1):6491. PubMed ID: 38499619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue.
    Shen J; Chen L; Liu J; Li A; Zheng L; Chen S; Li Y
    Chem Biol Drug Des; 2024 Apr; 103(4):e14517. PubMed ID: 38610074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
    Lu C; Wei XW; Wang Z; Zhou Z; Liu YT; Zheng D; He Y; Xie ZH; Li Y; Zhang Y; Zhang YC; Huang ZJ; Mei SQ; Liu JQ; Guan XH; Deng Y; Chen ZH; Tu HY; Xu CR; Chen HJ; Zhong WZ; Yang JJ; Zhang XC; Mok TSK; Wu YL; Zhou Q
    J Thorac Oncol; 2024 Apr; 19(4):601-612. PubMed ID: 37981218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
    Hu B; Wiesehöfer M; de Miguel FJ; Liu Z; Chan LH; Choi J; Melnick MA; Arnal Estape A; Walther Z; Zhao D; Lopez-Giraldez F; Wurtz A; Cai G; Fan R; Gettinger S; Xiao A; Yan Q; Homer R; Nguyen DX; Politi K
    Cancer Res; 2024 Apr; 84(8):1303-1319. PubMed ID: 38359163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in
    Schoenfeld AJ; Chan JM; Kubota D; Sato H; Rizvi H; Daneshbod Y; Chang JC; Paik PK; Offin M; Arcila ME; Davare MA; Shinde U; Pe'er D; Rekhtman N; Kris MG; Somwar R; Riely GJ; Ladanyi M; Yu HA
    Clin Cancer Res; 2020 Jun; 26(11):2654-2663. PubMed ID: 31911548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
    Lu K; Woodward BD; Boys J; Onaitis M; Husain H
    Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
    [No Abstract]   [Full Text] [Related]  

  • 15. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.
    Li Y; Wang N; Huang Y; He S; Bao M; Wen C; Wu L
    Cancer Genet; 2024 Jun; 284-285():34-42. PubMed ID: 38626533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
    Zhao B; Yao L; Ma W
    J Thorac Oncol; 2024 May; 19(5):e5-e6. PubMed ID: 38719426
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    Chen CY; Wang GS; Wei JC
    J Thorac Oncol; 2024 May; 19(5):e6-e7. PubMed ID: 38719427
    [No Abstract]   [Full Text] [Related]  

  • 18. Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report.
    Imai T; Yoshida T; Ohe Y
    Thorac Cancer; 2024 Mar; 15(9):749-751. PubMed ID: 38379439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.
    Lin TT; Xiong W; Chen GH; He Y; Long L; Gao XF; Zhou JL; Lv WW; Huang YZ
    Acta Pharmacol Sin; 2024 Apr; 45(4):867-878. PubMed ID: 38114644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
    Gray JE; Han JY; Telaranta-Keerie A; Huang X; Kohlmann A; Hodge R; Rukazenkov Y; Chmielecki J; Espenschied CR; Lefterova M; Wu YL; Ramalingam SS; Barrett JC; Odegaard JI
    J Mol Diagn; 2024 Jan; 26(1):73-84. PubMed ID: 37981090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.